Role of MS4A7 in Regulating Microglial Polarization and Neuroinflammation in Spinal Cord Injury via the

Xiangrui Li1, Junpeng Liu1, Youliang Deng2

  • 1Department of Anesthesiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

PubMed
Abstract

Insights

MS4A7 exacerbates spinal cord injury (SCI) by promoting pro-inflammatory microglial (M1) polarization via the cGAS-STING-NLRP3 pathway. Targeting MS4A7 may offer therapeutic benefits for SCI recovery.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Spinal cord injury (SCI) causes neurological deficits due to secondary inflammatory responses.
  • Microglial polarization (M1 pro-inflammatory, M2 anti-inflammatory) critically impacts SCI outcomes.
  • The role of MS4A7 in SCI-induced inflammation and microglial polarization is unknown.

Purpose of the Study:

  • To investigate the function of MS4A7 in modulating microglial polarization in SCI.
  • To elucidate the downstream effects of MS4A7 on neuroinflammation via the cGAS-STING-NLRP3 axis.
  • To evaluate MS4A7 as a potential therapeutic target for SCI.

Main Methods:

  • Utilized in vivo mouse SCI models and in vitro BV2 microglial cells.
  • Assessed microglial polarization using immunofluorescence, RT-qPCR, and ELISA for M1/M2 markers.
  • Investigated the cGAS-STING-NLRP3 pathway using genetic modulation and pharmacological inhibitors/activators.

Main Results:

  • MS4A7 expression was upregulated in SCI tissues.
  • MS4A7 knockdown reduced M1 polarization and pyroptosis, promoting M2 polarization and improving locomotor recovery.
  • MS4A7 overexpression enhanced M1 polarization and pyroptosis via the cGAS-STING-NLRP3 pathway.

Conclusions:

  • MS4A7 exacerbates SCI inflammation by promoting M1 microglial polarization through the cGAS-STING-NLRP3 axis.
  • Targeting MS4A7 and its associated pathways presents a potential therapeutic strategy for SCI.
  • This study provides novel insights into SCI pathophysiology and identifies MS4A7 as a promising therapeutic target.